Drug Profile
CTP 298
Alternative Names: CTP-298Latest Information Update: 10 Mar 2023
Price :
$50
*
At a glance
- Originator Concert Pharmaceuticals
- Developer Concert Pharmaceuticals; GSK
- Class Antiretrovirals; Isotopes; Oligopeptides; Organic deuterium compounds; Pyridines; Small molecules
- Mechanism of Action HIV protease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued HIV infections
Most Recent Events
- 06 Mar 2023 Concert Pharmaceuticals has been acquired by Sun Pharmaceutical Industries
- 26 Jun 2013 Discontinued - Preclinical for HIV infections in USA prior to 26 June 2013 (PO)